We had the pleasure of sitting down with Paul Rennie, CEO and Managing Director of Paradigm Biopharmaceuticals and asked him all the hard questions.
We discussed the recent milestone wins, the acceleration of PAR’s re-purposing of its pre-approved drugs, the company’s strong platform for growth, the recent investor road shows, the upcoming peer review publications and the main catalysts for the stock.
